Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 – Clinical Trial Optional)

0
33

Funding Opportunity ID:311961
Opportunity Number:RFA-DA-19-032
Opportunity Title:Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 – Clinical Trial Optional)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Grant
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.279
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See the funding announcement for eligibility details
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Jan 11, 2019
Close Date:Mar 20, 2019
Last Updated Date:Jan 11, 2019
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The purpose of this Funding Opportunity Announcement is to develop and evaluate Virtual Reality (VR) enhanced technologies that will support SUD treatment and recovery, provide treatment alternatives for chronic pain, or serve as next generation Clinical Research Tools which leverage data from the VR experience and identify digital markers that model SUD and comorbid mental illness disorders. The objective of Phase I (R43) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the VR platform in a larger sample. For VR digital therapeutics, data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA medical device.
Version:1





Visit the Official Webpage For More Details on Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 – Clinical Trial Optional)